Research programme: haemophilia protein therapy - Handok

Drug Profile

Research programme: haemophilia protein therapy - Handok

Alternative Names: HL 2353

Latest Information Update: 21 Aug 2014

Price : $50

At a glance

  • Originator Handok Pharmaceuticals
  • Developer Handok Inc
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 21 Aug 2014 Preclinical development is ongoing in South Korea
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
  • 22 Jun 2011 Preclinical trials in Haemophilia in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top